ArticleCancer discovery2017
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.
Abstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- The protein kinase IKK epsilon shapes the melanoma tumor microenvironment by modulating angiogenesis and the T-cell immunity.Molecular medicine (Cambridge, Mass.) · 2026Article
- TBK1 is a signaling hub in coordinating stress-adaptive mechanisms in head and neck cancer progression.Autophagy · 2025Article
- Emerging roles of TBK1 in cancer immunobiology.Trends in cancer · 2024Review
- Article
- Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.Molecular cancer therapeutics · 2023Article
- Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA.BMC biology · 2023Article
- Regulatory mechanisms of retinal ganglion cell death in normal tension glaucoma and potential therapies.Neural regeneration research · 2023Review
- Identification of 1Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Review
- NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets.International journal of molecular sciences · 2022Review
- The role of TBK1 in cancer pathogenesis and anticancer immunity.Journal of experimental & clinical cancer research : CR · 2022Review
- Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability.Molecular cancer therapeutics · 2022Article
- TBK1 Facilitates GLUT1-Dependent Glucose Consumption by suppressing mTORC1 Signaling in Colorectal Cancer Progression.International journal of biological sciences · 2022Article
- Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines.Frontiers in oncology · 2022Article
- ParsVNN: parsimony visible neural networks for uncovering cancer-specific and drug-sensitive genes and pathways.NAR genomics and bioinformatics · 2021Article
- Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review.Dermatology and therapy · 2021Review
- Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer.Cell reports · 2021Article
- Many Distinct Ways Lead to Drug Resistance inLife (Basel, Switzerland) · 2021Review
- Targeting AXL in NSCLC.Lung Cancer (Auckland, N.Z.) · 2021Review
- TANK-binding kinase 1 inhibitor GSK8612 enhances daunorubicin sensitivity in acute myeloid leukemia cells via the AKT-CDK2 pathway.American journal of translational research · 2021Article
Corrections and comments
- Commented on by
Authors and funding
27 authors.
Banu EskiocakDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Elizabeth A McMillanDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Saurabh MendirattaDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Rahul K KolliparaEugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, Texas.
Hailei ZhangThe Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts.
Caroline G HumphriesEugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, Texas.
Changguang WangDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Jose Garcia-RodriguezDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ming DingDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Aubhishek ZamanDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Tracy I RosalesDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ugur EskiocakChildren's Research Institute and the Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas.
Michael P SmithManchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Manchester, United Kingdom.
Jessica SudderthChildren's Research Institute and the Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas.
Kakajan KomurovDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Ralph J DeberardinisChildren's Research Institute and the Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas.
Claudia WellbrockManchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Manchester, United Kingdom.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yonghao YuDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Jef K De BrabanderDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Noelle S WilliamsDepartment of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas.
Lynda ChinDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Helen RizosMelanoma Institute, University of Sydney, Sydney, New South Wales, Australia.
Georgina V LongMelanoma Institute, University of Sydney, Sydney, New South Wales, Australia.
Ralf KittlerEugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, Texas.
Michael A WhiteDepartment of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, Texas. michael.white@utsouthwestern.edu.
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MUT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7MCOMPONENTS OF RAS-MEDIATED GROWTH CONTROLR01CA071443 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WHITE, MICHAEL A. · 1996 to 2015
$4.8MLung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8MMolecular and Biochemical Basis of mTORC1-mediated Feedback LoopsR01GM114160 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI YU, YONGHAO · 2015 to 2019
$1.6MTargeting Mechanistic Subtypes of Neoplastic DiseaseR35CA197717 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WHITE, MICHAEL A. · 2015 to 2015
$725kExploring synergy of combined BRAF-targeted therapy & immunotherapy for melanomaK08CA160692 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2012 to 2016
$713kNCI NIH HHS K08 CA160692NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA071443NCI NIH HHS R35 CA197717NCI NIH HHS U01 CA176284NIGMS NIH HHS R01 GM114160
Abstract
Genomic diversity among melanoma tumors limits durable control with conventional and targeted therapies. Nevertheless, pathologic activation of the ERK1/2 pathway is a linchpin tumorigenic mechanism associated with the majority of primary and recurrent disease. Therefore, we sought to identify therapeutic targets that are selectively required for tumorigenicity in the presence of pathologic ERK1/2 signaling. By integration of multigenome chemical and genetic screens, recurrent architectural variants in melanoma tumor genomes, and patient outcome data, we identified two mechanistic subtypes of BRAF
Indexed as
AnimalsBiomarkers, TumorCarcinogenesisDrug Resistance, NeoplasmHumansI-kappa B KinaseMAP Kinase Signaling SystemMelanomaMiceMutationProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafXenograft Model Antitumor AssaysBiomarkers, TumorBRAF protein, humanI-kappa B KinaseIKBKE protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins B-rafTBK1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.